Microsoft is planning a significant overhaul of Rust by utilising AI-driven systems to rewrite its legacy C and C++ code at an unprecedented scale. Microsoft may be preparing for one of the most ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Since taking over AstraZeneca in 2012, French-Australian Pascal Soriot has transformed the British pharmaceutical company that once lagged behind competitors into a global innovation powerhouse. The ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback